Search filters
Filters
Clear All

Phase

  • 1
  • 1
  • 3
  • 6
  • 4
  • 6

Found 6 T-Cell Lymphoma trials

A listing of T-Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 32422 A Phase 1-2 Open-Label Study of the Safety Pharmacokinetics Pharmacodynamics and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma

99 years and younger
All genders
The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.
Learn More

ASSESSMENT OF TREATMENT WITH VISIBLE LIGHT ACTIVATED SYNTHETIC HYPERICIN OINTMENT IN MYCOSIS FUNGOIDES PATIENTS

18-99 years
All genders
Phase 2
Interventional
The research study is being conducted to test the safety and efficacy of SGX301 (an investigational drug) in patients with mycosis fungoides in combination with light therapy using standard fluorescent lights. Eligible participants must have been diagnosed with mycosis fungoides, a form of Cutaneous T-cell Lymphoma. Participants will be asked …
Learn More

UPCC 33423 A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma (Lumin

99 years and younger
All genders
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Learn More

A051902: A randomized phase II study of CHO(E)P vs CC-486- CHO(E)P vs duvelisib- CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas

99 years and younger
All genders
This study evaluates the effects (good or bad) of adding a study drug (duvelisib or CC-486 (azacitidine)) to the usual combination of drugs. Eligible participants will be those with stage I-IV CD30 negative peripheral T-cell lymphoma that has not been previously treated.
Learn More

Senza5 CART5 to enhance immunotherapy against T cell non-Hodgkin lymphoma

99 years and younger
All genders
To determine the safety profile and recommended phase II dose (RP2D) for Senza5 CART5 in participants with CD5+ nodal T cell lymphoma following lymphodepletion with cyclophosphamide and fludarabine. recommended phase II dose of Senza5 CART5 (investigational product) maximum tolerated dose of Senza5 CART5 (investigational product); response rates to investigational therapy …
Learn More

Dermatology Clinic Repository Study

18-99 years
All genders
Observational
The purpose of this study is to obtain blood and/or skin tissues from consenting subjects who have been diagnosed with Cutaneous T-cell lymphoma (CTCL), solid organ transplant rejection or GVHD that will be used for current and/or future research. This research may provide information about the causes of these diseases …
Learn More